Allied Market Research


Hereceptin Biosimilars Market

Hereceptin Biosimilars Market Size, Share, Competitive Landscape and Trend Analysis Report by Type and by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Herceptin, also known as trastuzumab, is used as a medication for patients who suffer from cancer, which assists in controlling the growth and spread of cancer cells in the body. Herceptin biosimilars are essentially used to treat certain breast as well stomach cancers, and is also used in combination with other medicines for treatment. Herceptin biosimilars have gained traction recently as a preferred treatment method for cancers. This is attributed to the fact that Herceptin biosimilars act on the surface of the cancer cell by blocking the chemical signals that can stimulate uncontrolled growth. The major factors that fuel the growth of the market are escalating incidence of cancers globally, along with an increase in the incidence of breast cancers among women. In addition, the rising focus on the development of herceptin therapeutic biosimilars to treat HER2+ breast cancers supplement the market growth. However, stringent regulations regarding the approval of hereceptin biosimilars restrain the growth of the hereceptin biosimilars market. Moreover, the increasing focus of market players in the development of herceptin biosimilars will offer profitable opportunities for the growth of the market.

The report segments the market on the basis of type, application, and region. Based on type, the market is divided into uterine cancer, ovarian cancer, vaginal cancer, vulvar cancer, and cervical cancer. Based on end user, the market is classified into hospitals, drug stores, and other. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in this market are Mylan N.V., Amgen Inc., Mabion S.A., AryoGen Biopharma, Genor Biopharma, Celltrion Inc., Gedeon Richter Plc, The Instituto Vital Brazil, F. Hoffmann-La Roche AG, and Biocon.

Key Benefits

  • The study provides an in-depth analysis of the global herceptin biosimilars market, with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis¬†to enable stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by type assists in understanding various forms of herceptin biosimilars available.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

Hereceptin Biosimilars Market Report Highlights

Aspects Details
By Type
  • Capsule
  • Tablet
  • Others
By Application
  • Healthcare and Pharmaceuticals
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Mylan N.V., Mabion S.A., Genor Biopharma, The Instituto Vital Brazil, Gedeon Richter Plc, Amgen Inc., F. Hoffmann-La Roche AG, Biocon, AryoGen Biopharma, Celltrion Inc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Hereceptin Biosimilars Market

Global Opportunity Analysis and Industry Forecast, 2023-2032